Russia will soon test mRNA vaccine on cancer patients

The first people to receive the mRNA vaccine will include 30 melanoma patients at the Herzen Cancer Institute and another 30 patients at the Blokhin National Research Center for Oncology.

On September 23, Director of the Russian National Research Center for Epidemiology and Microbiology (Gamaleya), Alexander Gintsburg, said that the country's experts are ready to use mRNA vaccines for cancer patients in about a month.

A VNA reporter in Moscow quoted Mr. Gintsburg as saying that the application for approval to produce a vaccine using personalized mRNA technology for cancer patients has been submitted to the Russian Ministry of Health for approval.

In addition, groups of volunteers participating in this vaccine trial program have also been established and their genetic data has been determined.

In an earlier announcement, Mr. Gintsburg said the first people to receive the personalized mRNA vaccine will include 30 melanoma patients at the Herzen Cancer Research Institute and another 30 patients at the Blokhin National Research Center for Oncology.

Mr. Gintsburg expressed hope that the Gamaleya center and the Herzen and Blokhin institutes will soon be licensed to produce the first personalized melanoma vaccines.

According to the head of the Russian Federal Medical and Biological Agency (FMBA) Veronika Skvortsova, studies have proven the safety of personalized mRNA vaccines in helping to reduce the size and significantly slow down the growth of tumors (up to 60-80%).

In addition, studies also show an increase in survival rates for patients./.

(TTXVN/Vietnam+)

Source: https://www.vietnamplus.vn/nga-se-som-dung-thu-vaccine-mrna-cho-cac-benh-nhan-ung-thu-post1063568.vnp